Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 95

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 95
---
269 |     | $                  |    43,904 |
|                                       |     | Total                                        |     | $                  |   856,069 |     | $                  | 5,849,636 |
| Dallan Murray                         |     | Cash Severance                               |     | $                  |   944,850 |     | $                  | 1,259,800 |
| Executive Vice President,             |     | Accelerated Vesting of Equity Awards (2) (3) |     | —                  |           |     | $                  | 6,537,141 |
| Chief Customer Officer                |     | COBRA Continuation                           |     | $                  |    29,269 |     | $                  |    43,904 |
|                                       |     | Total                                        |     | $                  |   974,119 |     | $                  | 7,840,844 |

(1) Upon a termination of the named executive officer’s employment by us without “cause” or due to a “constructive termination” (each, as defined in the Severance Agreements described below) either upon or within 12 months following a change in control, the named executive officer is entitled to, subject to his or her execution and non-revocation of a release of claims: (i) an amount equal to 18 months of his or her base salary at the rate in effect immediately prior to the executive’s termination of employment payable in a cash lump sum; (ii) an amount equal to 100% of his or her annual target bonus assuming achievement of performance goals at 100% payable in a cash lump sum;

<div align='center'>70</div>

accelerated vesting on all outstanding and unvested equity awards; and

if the named executive officer elects to receive continued healthcare coverage pursuant to COBRA, payment or reimbursement for the executive and his or her eligible dependents for up to 18 months following the date of termination.

Pursuant to the terms of each of our 2011 Plan, 2014 Plan and 2018 Plan, where a successor corporation does not assume or grant substitute awards for our outstanding equity awards, all awards granted will immediately become exercisable or will vest without any further action or passage of time.

The stated dollar amounts in this row reflect the spread value of all unvested equity awards held by each named executive officer, assuming a stock price of $121.59 per share, the closing price